These are routine director share purchases that align non-executive directors' interests with shareholders but are too small in aggregate to signal conviction. Monitor next quarterly filing for any change in executive insider trading patterns.
Price Chart
Executive Summary
GSK plc filed a Form 6-K reporting open-market purchases of ordinary shares and American Depositary Shares by its Non-Executive Chair and seven independent non-executive directors on September 18, 2026. The transactions are routine director shareholdings and carry no material financial or operational implications for the company.
Key Facts
- Non-Executive Chair Sir Jonathan Symonds purchased 1,500 ordinary shares at £18.8110 each on the London Stock Exchange.
- Six independent non-executive directors (Liz McKee Anderson, Charles Bancroft, Dr Anne Beal, Dr Hal Dietz, Dr Jeannie Lee, Dr Vishal Sikka) each purchased ADS at $49.8534 per ADS on the NYSE.
- Senior Independent Non-Executive Director Charles Bancroft purchased 1,734 ADS; other directors purchased between 626 and 994 ADS.
- Independent Non-Executive Director Roy Jackobs purchased 936 ordinary shares at £18.8100 each on the London Stock Exchange.
- All transactions occurred on September 18, 2026, and were reported as initial notifications.
Financial Impact
Total aggregate value of purchases is approximately £28,216 (Symonds) + £17,606 (Jackobs) + $198,000 (combined ADS purchases at $49.8534 each), immaterial relative to GSK's market cap.
Risk Factors
- No material risks identified from this routine PDMR transaction notification.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-008503 |
| Document: 0001654954-26-008503-index-headers.html | 0001654954-26-008503 |
| Document: 0001654954-26-008503-index.html | 0001654954-26-008503 |
| Document: 0001654954-26-008503.txt | 0001654954-26-008503 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 28, 2026 2d ago | 6-K | $48.74 | awaiting T+5 | awaiting T+5 | $49.74 (+2.04%) |
Oct 26, 2026 4d ago | 6-K | $51.10 | awaiting T+5 | awaiting T+5 | $49.74 (−2.67%) |
Oct 26, 2026 4d ago | 6-K | $51.10 | awaiting T+5 | awaiting T+5 | $49.74 (−2.67%) |
Oct 26, 2026 4d ago | 6-K | $51.10 | awaiting T+5 | awaiting T+5 | $49.74 (−2.67%) |
Oct 26, 2026 4d ago | 6-K | $51.10 | awaiting T+5 | awaiting T+5 | $49.74 (−2.67%) |
Oct 21, 2026 9d ago | 6-K | $50.02 $50.94 | ▲ +1.84% | ▲ +2.28% | $49.74 (−0.57%) |
Oct 19, 2026 11d ago | 6-K | $49.46 $51.10 | ▲ +3.32% | ▲ +3.46% | $49.74 (+0.56%) |
Oct 19, 2026 11d ago | 6-K | $49.46 $51.10 | ▲ +3.32% | ▲ +3.46% | $49.74 (+0.56%) |
Oct 15, 2026 15d ago | 6-K | $49.02 $51.21 | ▲ +4.47% | ▲ +5.48% | $49.74 (+1.46%) |
Oct 14, 2026 16d ago | 6-K | $47.87 $50.02 | ▲ +4.49% | ▲ +4.04% | $49.74 (+3.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers